Search hospitals > Michigan > Troy
William Beaumont Hospital - Troy
Claim this profileTroy, Michigan 48085
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
218 reported clinical trials
24 medical researchers
Summary
William Beaumont Hospital - Troy is a medical facility located in Troy, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. William Beaumont Hospital - Troy is involved with conducting 218 clinical trials across 306 conditions. There are 24 research doctors associated with this hospital, such as Laura K. Gowans, Dana Zakalik, Andrew A. Muskovitz, and Daniel J. Krauss.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Laura K. GowansBeaumont Children's Hospital-Royal Oak4 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
40 reported clinical trials
92 drugs studied
Dana ZakalikBeaumont Hospital - Farmington Hills1 year of reported clinical research
Expert in Cancer
Studies Ovarian Cancer
12 reported clinical trials
46 drugs studied
Andrew A. MuskovitzWilliam Beaumont Hospital-Royal Oak3 years of reported clinical research
Studies Cancer
Studies Colorectal Cancer
8 reported clinical trials
19 drugs studied
Daniel J. KraussWilliam Beaumont Hospital - Troy2 years of reported clinical research
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
6 reported clinical trials
30 drugs studied
Clinical Trials running at William Beaumont Hospital - Troy
Breast Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Cancer
Lung Cancer
Esophageal Carcinoma
Non-Small Cell Lung Cancer
Pancreatic Cancer
Ovarian Cancer
Prostate Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at William Beaumont Hospital - Troy?
William Beaumont Hospital - Troy is a medical facility located in Troy, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. William Beaumont Hospital - Troy is involved with conducting 218 clinical trials across 306 conditions. There are 24 research doctors associated with this hospital, such as Laura K. Gowans, Dana Zakalik, Andrew A. Muskovitz, and Daniel J. Krauss.